FLIXONASE® ALLERGY & 

HAYFEVER RELIEF

What is Flixonase

Flixonase Allergy & Hayfever 24 hour is a once daily nasal spray used to prevent and treat seasonal allergic rhinitis ( e.g. hayfever) and perennial rhinitis in adults aged 18 years and over. Use only on medical advice in adolescents aged 12-17 years.

Flixonase contains a corticosteroid called fluticasone propionate, which treats inflamed tissue by producing an anti-inflammatory effect, constricting blood vessels in the nose and targeting 6 key allergic substances that cause your allergy symptoms (4/5). The tiny amounts sprayed into your nose help to reduce swelling and irritation.

When you spray Flixonase into your nose it helps relieve the itching, sneezing and blocked or runny nose, as well as sinus pain and congestion.

HOW IT WORKS:

FLIXONASE® ALLERGY & HAYFEVER RELIEF 

Flixonase pack

   

Outperforms  antihistamine tablets.1-3

FLIXONASE® Allergy & Hayfever Relief targets 6 key allergic substances. Antihistamine tablets only target 1.1,4,5

LEARN WHICH 6 KEY
ALLERGIC SUBSTANCES
FLIXONASE® HELPS  TARGET:

  • Histamine
  • Platelet Activating Factor
  • Prostaglandins
  • Tryptases
  • Interleukins
  • Leukotrienes
24 Hour Relief

24 HOUR RELIEF OF:

Symptom Checklist

THE BENEFITS OF FLIXONASE®

 

24 Hour

Offers 24-hour relief from all nasal allergy symptoms including congestion, runny nose, and sneezing.

Non Drowsy

Non-drowsy formula.

Nose

Works directly at the source where you need it most.

 

Blocks 6

Targets 6 key allergic substances. Antihistamine tablets only target 1.1,4,5

Graph

Outperforms  antihistamine tablets.1-3

Envelope

 Supported by website with education and useful tips.

FAQ

Flixonase bottle

 

 

Flixonase contains fluticasone propionate 50mcg per spray. ALWAYS READ THE LABEL. Use only as directed. For the prevention and treatment of seasonal and allergic rhinitis including hayfever. If symptoms persist, see your healthcare professional.

 

Flixonase is a registered trademark of the GSK group of companies or its licensor. Auckland, New Zealand. TAPS PP8551 

The information on this site is intended for visitors from New Zealand only. See our Terms and Conditions and Privacy Policy.

 

 

1.  Australian Medicines Handbook 2016, AMH Pty Ltd; Adelaide. 2. Bousquet J et al. Allergy 2008;63(Suppl 86):8–160. 3. Wallace DV et al. J Allergy Clin Immunol 2008;122:S1–84. 4. Bachert C & Geveart P. Allergy 1999;54(Suppl 57):116–23.  5. Wiseman LR & Benfield P. Drugs 1997;53:885–907.

 

 

Flixonase contains fluticasone propionate 50mcg per spray. ALWAYS READ THE LABEL. Use only as directed. For the prevention and treatment of seasonal and allergic rhinitis including hayfever. If symptoms persist, see your healthcare professional.

 

Flixonase is a registered trademark of the GSK group of companies or its licensor. Auckland, New Zealand. TAPS XXXXXXX

The information on this site is intended for visitors from New Zealand only. See our Terms and Conditions and Privacy Policy.

 

 

1.  Australian Medicines Handbook 2016, AMH Pty Ltd; Adelaide. 2. Bousquet J et al. Allergy 2008;63(Suppl 86):8–160. 3. Wallace DV et al. J Allergy Clin Immunol 2008;122:S1–84. 4. Bachert C & Geveart P. Allergy 1999;54(Suppl 57):116–23.  5. Wiseman LR & Benfield P. Drugs1997;53:885–907.

 

 

Flixonase contains fluticasone propionate 50mcg per spray. ALWAYS READ THE LABEL. Use only as directed. For the prevention and treatment of seasonal and allergic rhinitis including hayfever. If symptoms persist, see your healthcare professional.

 

Flixonase is a registered trademark of the GSK group of companies or its licensor. Auckland, New Zealand. TAPS XXXXXXX

The information on this site is intended for visitors from New Zealand only. See our Terms and Conditions and Privacy Policy.

 

 

1.  Australian Medicines Handbook 2016, AMH Pty Ltd; Adelaide. 2. Bousquet J et al. Allergy 2008;63(Suppl 86):8–160. 3. Wallace DV et al. J Allergy Clin Immunol 2008;122:S1–84. 4. Bachert C & Geveart P. Allergy 1999;54(Suppl 57):116–23.  5. Wiseman LR & Benfield P. Drugs1997;53:885–907.